1. Home
  2. CDP vs DNLI Comparison

CDP vs DNLI Comparison

Compare CDP & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COPT Defense Properties of Beneficial Interest

CDP

COPT Defense Properties of Beneficial Interest

HOLD

Current Price

$36.52

Market Cap

3.6B

Sector

Real Estate

ML Signal

HOLD

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

HOLD

Current Price

$25.68

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDP
DNLI
Founded
1988
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.7B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
CDP
DNLI
Price
$36.52
$25.68
Analyst Decision
Buy
Strong Buy
Analyst Count
7
14
Target Price
$34.57
$34.33
AVG Volume (30 Days)
1.2M
1.9M
Earning Date
04-27-2026
05-06-2026
Dividend Yield
4.14%
N/A
EPS Growth
8.94
N/A
EPS
0.34
N/A
Revenue
$763,923,000.00
N/A
Revenue This Year
$1.18
N/A
Revenue Next Year
$3.71
$408.85
P/E Ratio
$107.12
N/A
Revenue Growth
1.41
N/A
52 Week Low
$26.91
$12.58
52 Week High
$38.06
$27.30

Technical Indicators

Market Signals
Indicator
CDP
DNLI
Relative Strength Index (RSI) 64.51 62.78
Support Level $30.86 $17.77
Resistance Level N/A N/A
Average True Range (ATR) 0.72 1.12
MACD 0.00 0.02
Stochastic Oscillator 68.87 58.58

Price Performance

Historical Comparison
CDP
DNLI

About CDP COPT Defense Properties of Beneficial Interest

COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Share on Social Networks: